newsfilter
← Latest News
Business Wire·

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

FB102 Received Fast Track Designation in Celiac Disease Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases,